Use of DNA variations as an indicator of patient response to medicines is one study underway that taps the newly available Vanderbilt University DNA databank, BioVU. The databank--currently available only to Vanderbilt researchers and collaborators--contains de-identified biological samples from 75,000 individuals collected since 2007 and has linked them the matching electronic medical records. Article